Insmed/$INSM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Ticker

$INSM
Primary listing

Industry

Biotechnology

Employees

1,271

ISIN

US4576693075

Insmed Metrics

BasicAdvanced
$18B
-
-$5.89
0.79
-

What the Analysts think about Insmed

Analyst ratings (Buy, Hold, Sell) for Insmed stock.

Bulls say / Bears say

Insmed's experimental drug for pulmonary arterial hypertension (PAH) demonstrated significant efficacy in a Phase 2b study, leading to a 29% surge in stock price and plans for Phase 3 trials in late 2025. (biopharmadive.com)
The company's lead product, ARIKAYCE, achieved a 19% annual revenue growth in 2024, totaling $363.7 million, exceeding guidance and indicating strong market demand. (pr.comtex.com)
Brensocatib, targeting non-cystic fibrosis bronchiectasis, showed positive Phase 3 results, with an FDA New Drug Application accepted and a potential U.S. launch in mid-2025. (pr.comtex.com)
Insmed reported a net loss of $913.8 million for 2024, raising concerns about its financial sustainability despite revenue growth. (pr.comtex.com)
The company carries a high debt load of $1.1 billion, which could limit financial flexibility and increase risk for investors. (panabee.com)
Insider selling, including CEO William Lewis selling 18,750 shares in March 2025, may signal potential concerns about the company's future prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

Insmed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Insmed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INSM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs